Hormone therapy and your brain: what the new Karolinska study means (and what it doesn't)

By Kevin Wolfe, Founder & CEO

Reviewed by Kindr Health Clinical Team

Published November 5, 2026 · Updated November 5, 2026

The question patients will bring today

This morning, the Washington Post asked a question many women will bring into clinic: can hormone therapy lower the risk of Alzheimer's and dementia? The piece centers new research on estrogen and how women's brains age — and it is easy to read the headlines as a promise that menopausal hormone therapy (HT) protects against dementia.

It doesn't. The study behind the news looked at blood-vessel marks on MRI, not dementia diagnoses. It found associations, not proof that starting hormones will prevent Alzheimer's. That distinction matters before anyone changes a prescription based on a news alert.

What the Neurology study actually found

Researchers led by a Karolinska Institutet team published the work November 4, 2026, in Neurology, the journal of the American Academy of Neurology. They studied 352 cognitively unimpaired Swedish women from the Gothenburg H70 Birth Cohort. Everyone had brain MRI at about age 70, and many were scanned again at 75.

The team looked at lifetime estrogen-related factors:

• Reproductive lifespan — years from first period to menopause (or surgical removal of the ovaries). The average was about 37 years.
• Oral contraceptive use — about 73% of participants had ever used birth control pills.
• Menopausal hormone therapy — about 61% had used or were still using it.

They scored four MRI signs of cerebral small-vessel disease (damage to the brain's tiniest blood vessels): white-matter hyperintensities, microbleeds, lacunes (small cavities), and enlarged spaces around blood vessels. Small-vessel disease is linked to stroke, cognitive impairment and dementia risk over time — but this study measured the vessel marks themselves, not who developed dementia.

After adjusting for factors such as education, pregnancies and breastfeeding, a longer reproductive lifespan was associated with 8% lower odds of having two or more signs of small-vessel disease.

In a separate analysis that also accounted for education and cardiometabolic conditions, menopausal hormone therapy use was associated with a lower small-vessel disease burden, including fewer microbleeds and fewer enlarged perivascular spaces. Oral contraceptive use and menopausal hormone therapy were each associated with greater integrity of the brain's white-matter microstructure — an early marker of healthier tissue. Women who had used oral contraceptives during their reproductive years and later received menopausal hormone therapy showed the most favorable vascular brain profile in this cohort.

Senior author Anna Marseglia, PhD, of Karolinska Institutet, noted that estrogen has protective effects on brain cells and blood vessels, and that women's higher Alzheimer's rates may relate in part to estrogen fluctuations across life. The authors frame the work as adding to how scientists think about cerebrovascular pathways in women's brain aging — not as a prescription change.

What the study does not mean

The limits are as important as the favorable signal:

• It is observational. Association is not causation. Women who used hormones may differ in ways the study could not fully capture.
• Hormone use was self-reported. People may not remember every detail accurately. The researchers could not track individual hormone levels over time.
• Dose, formulation, route and timing were largely missing. The paper lacked detailed information on when treatment started relative to menopause, what was taken, and for how long — so it cannot answer the "window of opportunity" questions clinicians debate every day.
• It was not a dementia trial. Outcomes were MRI markers of small vessels and white-matter integrity in cognitively unimpaired women, not Alzheimer's diagnoses or cognitive endpoints that would support a prevention claim.
• Authors say so themselves. First author Giulia Lorenzon and colleagues caution that the results "cannot therefore be used as a basis for recommending hormone therapy for preventive purposes." The American Academy of Neurology's press summary is equally clear: the study shows associations and does not prove that reproductive lifespan or hormone use directly protect the brain; clinical trials would be needed to establish cause and effect.

So if a headline asks whether hormone therapy lowers Alzheimer's risk, the honest short answer from this paper is: we still don't know — and this study was not designed to prove that.

What still guides menopause care

While brain-prevention headlines will travel fast, day-to-day care for hot flashes and night sweats still rests on menopause guidelines, not on this MRI study.

In October 2026, the American College of Obstetricians and Gynecologists (ACOG) published its most comprehensive menopause guidance to date. It covers hormone therapy, nonhormonal medicines, and non-drug approaches for vasomotor symptoms (hot flashes and night sweats), sleep and mood. ACOG supports hormone therapy as an option for many women, chosen through shared decision-making that weighs symptoms, age and medical history, baseline risks of heart disease, breast cancer and blood clots, and personal goals.

Timing still matters. If a woman and her clinician choose hormone therapy, ACOG recommends starting before age 60 or within 10 years of the start of spontaneous menopause, for people without reasons to avoid it.

Separately, the American College of Physicians (ACP) recommends estrogen (with a progestogen if you have a uterus, or estrogen alone if you don't) as first-line treatment for women seeking help with hot flashes and night sweats, based on the most favorable balance of benefits and harms among options it reviewed.

"First-line" is not "risk-free," and it is not "for dementia prevention." Hormone therapy still has risks that depend on who you are, when you start, and what you take — including blood clots, stroke and, with some estrogen-plus-progestogen regimens, breast cancer. Estrogen without a progestogen raises endometrial cancer risk in women who have a uterus. Standard reasons not to use systemic HT include a history of blood clots, stroke, a current or past heart attack, active liver disease, unexplained vaginal bleeding, and personal history of breast cancer. Bring a complicated history up with your clinician early.

In November 2025, the FDA asked makers of menopausal hormone therapy to change their labels. The change removes language on heart disease, breast cancer and probable dementia from the boxed warning. Systemic product labels still keep cardiovascular and breast cancer warnings, and estrogen-alone systemic products keep a boxed warning about endometrial cancer. That labeling change applies only to FDA-approved products.

If hormones aren't right for you

ACOG's guidance also reviews evidence-based nonhormonal options for people who cannot use hormones or prefer not to:

• SSRIs and SNRIs. Certain antidepressants can reduce hot flashes and may also help if depression is part of the picture. Some can interact with tamoxifen, so share your full medication list.
• Neurokinin receptor antagonists. A newer class that acts on the brain's temperature-control pathways:
  • fezolinetant (Veozah), which carries an FDA boxed warning for rare but serious liver injury and requires liver blood tests. Prescribing information
  • elinzanetant (Lynkuet). It can cause sleepiness and other nervous-system effects, requires liver blood tests before starting, and must not be used during pregnancy. Its label also warns: "Seizure was reported in patients taking LYNKUET... Use LYNKUET with caution in patients with a history of seizures or with conditions that potentially lower the seizure threshold." Prescribing information

ACOG also recommends non-drug approaches such as cognitive behavioral therapy, mindfulness, exercise, clinical hypnosis and acupuncture, usually alongside medication. ACOG says the evidence does not support the safety or effectiveness of herbal supplements or phytoestrogens for menopause symptoms.

Questions to bring to your clinician

• Given the news about estrogen and the brain, what does — and doesn't — apply to my situation?
• Are my hot flashes, night sweats or sleep changes likely related to perimenopause or menopause?
• Given my age and how long it's been since menopause started, is hormone therapy a reasonable option for symptoms, not for dementia prevention?
• Is there anything in my personal or family history (clots, stroke, heart disease, breast cancer, liver disease) that would make hormone therapy unsafe for me?
• What are the benefits and risks for me specifically, and how do they compare with nonhormonal options?
• Which form (pill, patch, gel, spray or ring) would make sense, and do I need a progestogen?
• If I don't want or can't use hormones, which nonhormonal option fits my health history — and what monitoring would I need?

The bottom line

A new Neurology study from Karolinska-linked researchers found that longer reproductive years and a history of oral contraceptive and menopausal hormone therapy use were associated with fewer small-vessel disease marks and greater white-matter integrity on brain MRI in 352 cognitively unimpaired older women. That is a meaningful scientific signal about estrogen and cerebrovascular aging. It is not proof that hormone therapy prevents Alzheimer's or dementia, and the authors explicitly say the results should not be used to recommend HT for prevention.

For bothersome hot flashes and night sweats, hormone therapy remains an evidence-based option when appropriate — with timing before 60 or within 10 years of menopause still central in ACOG's guidance, and ACP recommending hormonal therapy as first-line for vasomotor symptoms. Good nonhormonal medicines exist when hormones aren't right. Use the headlines as a conversation starter with a clinician, not as a reason to start HT solely to "protect your brain."

If hot flashes or night sweats are disrupting your days or your sleep, you can talk with a board-certified Kindr Health clinician. They can help you look at all your options, hormonal and nonhormonal, including their benefits and risks, and decide whether any of them fits you. Kindr Health clinicians may prescribe compounded hormone therapy; compounded medications are not FDA-approved, and the FDA labeling changes described above apply only to FDA-approved products.

For education only, not medical advice. Talk with a licensed clinician about your situation.

Medically reviewed by Kindr Health Clinical Team
Last updated: November 5, 2026